查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1775587

单株抗体市场：2025年至2030年的预测

Monoclonal Antibodies Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 142 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

单株抗体市场预计将从 2025 年的 2,014.29 亿美元成长到 2030 年的 3,407 亿美元，复合年增长率为 11.08%。

免疫系统会自然产生抗体来应付感染疾病。单株抗体是指旨在增强人体自然免疫系统对入侵者（如癌症和感染疾病）反应的分子。由于单株抗体是在实验室中开发的，因此它们被归类为人造药物。单株抗体优于其他类型的感染疾病治疗方法，因为它们是特异性设计用于针对感染过程的重要部分。它们是透过将白血球暴露于特定的病毒蛋白质所产生的。然后对它们进行克隆以大量生产针对该病毒的抗体。单株抗体已被开发用于治疗多种病毒感染疾病，包括伊波拉出血热和狂犬病。单株抗体已开发用于治疗多种病毒感染疾病，包括伊波拉出血热和狂犬病，在临床试验证明其可有效减轻疾病严重程度后，在 COVID-19 大流行期间被广泛使用。

推动单株抗体市场成长的因素：

  • 单株抗体的需求不断增加

根据世界卫生组织 (WHO) 的数据，2020 年全球约有 1,000 万人死于癌症。单株抗体在癌症治疗中非常有效，这使得对价格合理的抗癌药物的需求日益增长。此外，在新冠疫情期间，许多单株抗体临床试验旨在开发新的药物疗法，并获得了广泛的产品核可，可用于紧急治疗新冠疫情。

市场也正在不断发展以满足对单株抗体医药品日益增长的需求，这些药物旨在为复杂和严重的疾病提供高度特异性的治疗，进一步刺激单株抗体市场的成长潜力。

单株抗体市场的地理展望：

  • 预计北美将在预测期内占据主要市场占有率

北美国家拥有发达的医疗保健基础设施，但该地区的大量饮酒和垃圾速食文化导致肥胖，使人们患癌症的风险更高。

此外，新的疫苗和药物正在研发中，以帮助治疗癌症患者。 Amneal Pharmaceuticals宣布在美国推出Bevacizumab（Alymsys）。该药物是Bevacizumab（Avastin，基因泰克）的生物相似药。Bevacizumab由mAbxience开发。它可用于治疗转移性大肠直肠癌、第一线非鳞状非小细胞肺癌、持续性、復发性和转移性子宫颈癌以及上皮性卵巢癌、输卵管癌和原发性腹膜癌。

目录

第一章 引言

  • 市场概览
  • 市场定义
  • 市场区隔

第二章调查方法

  • 调查数据
  • 先决条件

第三章执行摘要

  • 调查重点

第四章 市场动态

  • 市场驱动因素
  • 市场限制
  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 业内竞争对手之间的竞争
  • 产业价值链分析

5. 单株抗体市场（依适应症划分），2020 年至 2030 年

  • 介绍
  • 发炎性疾病
  • 癌症
  • 微生物疾病
  • 其他的

6. 单株抗体市场（依来源划分），2020 年至 2030 年

  • 介绍
  • 人性化
  • 人类
  • 嵌合体
  • 老鼠

7. 单株抗体市场（按应用划分），2020 年至 2030 年

  • 介绍
  • 诊断
  • 治疗
  • 其他的

8. 单株抗体市场（依最终用户划分），2020 年至 2030 年

  • 介绍
  • 医院和诊所
  • 实验室

9. 单株抗体市场（按地区划分），2020 年至 2030 年

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 印度
    • 泰国
    • 台湾
    • 其他的

第十章竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 供应商竞争力矩阵

第十一章 公司简介

  • Eli Lilly and Company
  • AbbVie, Inc.
  • Novartis AG
  • Bristol Myers Squibb
  • F.Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • Amgen Inc.
  • Merck & Co. Inc.
  • AstraZeneca PLC
简介目录
Product Code: KSI061610595

The Monoclonal Antibodies Market is expected to grow from US$201.429 billion in 2025 to US$340.700 billion in 2030, at a CAGR of 11.08%.

The immune system naturally produces antibodies in response to an infection. A monoclonal antibody is a molecule designed to enhance the body's natural immune system response against an invader, such as cancer or an infection. It is developed in a laboratory and hence comes under man-made drugs. Monoclonal antibodies are created to specifically target an essential part of the infectious process, and therefore, they have an advantage over other types of treatment for infections. It is created by exposing a white blood cell to a particular viral protein. It is then cloned to mass-produce antibodies, which target that virus. The monoclonal antibodies are developed to treat several viral infections, such as Ebola and rabies. They were widely used during the COVID-19 pandemic, as the clinical trials proved that the antibodies are effective in reducing the severity.

Monoclonal Antibodies Market Growth Drivers:

  • Increased demand for monoclonal antibodies

According to the World Health Organization, around 10 million people died due to cancer worldwide in 2020. For cancer treatment, monoclonal antibodies are significantly helpful, therefore, there is an increasing need for affordable cancer therapies. Moreover, during the COVID-19 pandemic, many monoclonal antibodies' clinical trials took place in order to develop novel drug therapy, as well as a wide range of product approvals were made for emergency use in COVID-19 treatment.

With its growing demand, the market players have a strong focus on the development as well as the discovery of monoclonal antibody therapeutics. The step has been taken to offer highly specific treatment for complex and severe diseases. Furthermore, it will stimulate the monoclonal antibodies market growth potential.

Monoclonal Antibodies Market Geographical Outlook:

  • North America is expected to hold a significant market share during the anticipated period

North American countries have a well-developed healthcare infrastructure. However, the high intake of alcohol and junk/fast food culture in this region is leading to obesity and putting the population at a high risk of being infected with cancer.

Furthermore, new vaccines/drugs are being developed to help in the treatment of cancer patients. Amneal Pharmaceuticals announced the launch of bevacizumab-maly (Alymsys) in the United States. The drug is a biosimilar reference of bevacizumab (Avastin, Genentech). Bevacizumab-maly is developed by mAbxience. The drug will be useful in the treatment of metastatic colorectal cancer, first-line non-squamous non-small cell lung cancer, persistent, recurrent, or metastatic cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Monoclonal Antibodies Market Segmentation:

By Indication

  • Inflammatory Disease
  • Cancer
  • Microbial Disease
  • Others

By Source

  • Humanized
  • Human
  • Chimeric
  • Murine

By Application

  • Diagnostic
  • Therapeutic
  • Others

By End-User

  • Hospitals & Clinics
  • Research Laboratories

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Market Segmentation

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. MONOCLONAL ANTIBODIES MARKET, BY INDICATION (2020-2030)

  • 5.1. Introduction
  • 5.2. Inflammatory Disease
  • 5.3. Cancer
  • 5.4. Microbial Disease
  • 5.5. Others

6. MONOCLONAL ANTIBODIES MARKET, BY SOURCE (2020-2030)

  • 6.1. Introduction
  • 6.2. Humanized
  • 6.3. Human
  • 6.4. Chimeric
  • 6.5. Murine

7. MONOCLONAL ANTIBODIES MARKET, BY APPLICATION (2020-2030)

  • 7.1. Introduction
  • 7.2. Diagnostic
  • 7.3. Therapeutic
  • 7.4. Others

8. MONOCLONAL ANTIBODIES MARKET, BY END-USER (2020-2030)

  • 8.1. Introduction
  • 8.2. Hospitals & Clinic
  • 8.3. Research Laboratories

9. MONOCLONAL ANTIBODIES MARKET, BY GEOGRAPHY (2020-2030)

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. USA
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. Germany
    • 9.4.2. France
    • 9.4.3. United Kingdom
    • 9.4.4. Spain
    • 9.4.5. Others
  • 9.5. Middle East and Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. UAE
    • 9.5.3. Others
  • 9.6. Asia Pacific
    • 9.6.1. China
    • 9.6.2. Japan
    • 9.6.3. South Korea
    • 9.6.4. India
    • 9.6.5. Thailand
    • 9.6.6. Taiwan
    • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Vendor Competitiveness Matrix

11. COMPANY PROFILES

  • 11.1. Eli Lilly and Company
  • 11.2. AbbVie, Inc.
  • 11.3. Novartis AG
  • 11.4. Bristol Myers Squibb
  • 11.5. F.Hoffmann-La Roche Ltd.
  • 11.6. Johnson & Johnson Services, Inc.
  • 11.7. Amgen Inc.
  • 11.8. Merck & Co. Inc.
  • 11.9. AstraZeneca PLC